Ahead of the AbbVie Vote, Apogee Updates Share Counts, Lifts Golden Parachute Payouts, and Discloses Litigation
APGE has more than doubled off its 52-week low of $34.34.
Summary
Apogee's supplemental proxy updates share counts, raises golden parachute payouts for executives, discloses a stockholder lawsuit, and confirms German antitrust clearance ahead of the August 11 vote on AbbVie's $135.11/share acquisition.
Key Events · M&A and Partnerships · APGE
-
Updated Share Counts and Vote Threshold
Outstanding voting common stock increased to 62,140,183 shares, raising the majority vote requirement to 31,070,092 shares. Director and executive officer ownership rose to 1,412,999 shares (2.27%).
-
Higher Golden Parachute Compensation
CEO Michael Henderson's total golden parachute compensation increased to $61.3 million (from $56.4 million), Carl Dambkowski to $25.6 million (from $21.6 million), and Jane Pritchett Henderson to $25.3 million (from $20.7 million), reflecting updated equity values.
-
Stockholder Litigation Disclosed
A complaint (Smith v. Apogee) was filed July 23, 2026, alleging the proxy omitted material information. Apogee also received demand letters with similar allegations and believes the claims are without merit.
-
German Antitrust Clearance Obtained
Parent received unconditional clearance from the German FCO on July 27, 2026, satisfying one closing condition. An Australian ACCC notification was filed, with Phase 1 review expiring September 7, 2026.
Analysis · APGE · Life Sciences
With the August 11 stockholder vote on its $10.9B acquisition by AbbVie approaching, Apogee filed supplemental proxy materials that refresh several critical figures. The outstanding share count has been revised upward, pushing the majority vote threshold to 31.1 million shares. Golden parachute compensation for top executives also moved materially higher—CEO Michael Henderson's package now stands at $61.3 million, up from $56.4 million, driven by increased equity values. Additionally, the company disclosed a stockholder lawsuit filed on July 23 alleging inadequate disclosures, while confirming German antitrust clearance and noting that an Australian review expires on September 7. These updates equip stockholders with the latest data for an informed vote, though the litigation introduces a potential risk to deal timing.
At the time of this filing, APGE was trading at $134.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $34.34 to $134.46. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.